Table 2 List of proteins with altered expression in COPD patients vs the controls, as per the MALDI sequencing analysis
From: Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD
S. No. | Name of the identified proteins | Fold change | Predicted function |
|---|---|---|---|
1 | Preg. Zone Protein (PZP) | −3.6 | Protease inhibitor, able to inhibit all four classes of proteases |
2 | α-2 Macroglobulin(A2MG) | −2.5 | Protease inhibitor, able to inhibit all four classes of proteases |
3 | Peptidase Inhibitor (PI16) | −2.3 | Serine Protease Inhibitor |
4 | Serotransferrin TRFE_Human) | −2.0 | To prevent oxidative damage |
5 | Cytokine suppressor (SOCS-3) | 3.1 | SOCS-3; Suppressor of cytokine signaling. SOCS3 involved in the negative regulation of cytokines. |
6 | Carboxy peptidase B2,(CBPB2) | 2.4 | Carboxy peptidase (cleave basic amino residues), plays a major role in the breakdown of the extracellular matrix |
7 | Matrix Metallo Protease −2 (MMP-II) | 2.6 | MMP-2 or Gelatinase A or type IV Collagenase, breakdown extracellular matrix |
8 | Human Leukocyte Elastase (HLE) | 2.8 | Serine Protease that hydrolyzes many proteins in addition to Elastin |